Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Fatigue, Headache, Malaise
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch); Moderate injection site redness; Mild injection site swelling; Severe fatigue with significant interference with activity; Headache and no interference with activity; Joint pain and no interference with activity; Moderate muscle pain with some interference with activity; Mild fever (100.4 to 101.2 °F); This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and FATIGUE (Severe fatigue with significant interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Severe fatigue with significant interference with activity), HEADACHE (Headache and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and PYREXIA (Mild fever (100.4 to 101.2 °F)). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Severe fatigue with significant interference with activity), HEADACHE (Headache and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and PYREXIA (Mild fever (100.4 to 101.2 °F)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).         Concomitant medication and treatment information was not reported.  Patient experienced events during the two days after COVID-19 vaccination, which occurred on Monday, 18 Dec 2023 and Tuesday 19 Dec 2023.   This case was linked to US-MODERNATX, INC.-MOD-2024-756041 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756041:Same reporter